Pluri Inc.
Biotechnology firm with 3D cell-expansion tech for manufacturing cell-based products.
PLUR | TA
Overview
Corporate Details
- ISIN(s):
- US72942G2030
- LEI:
- Country:
- Israel
- Address:
- Park Building No. 5, 3508409 Haifa
- Website:
- https://pluri-biotech.com/
- Sector:
- Manufacturing
Description
Pluri Inc. is a biotechnology company specializing in proprietary 3D cell-expansion technology. The company develops and operates platforms for the scalable, consistent, and cost-effective manufacturing of cell-based products. Its technology is applied across multiple sectors, including regenerative medicine, cell therapy, food technology, and agriculture technology (AgTech). Pluri aims to create next-generation cell-based products to improve human wellbeing and establishes partnerships to leverage its platform. The company also provides Contract Development and Manufacturing Organization (CDMO) services.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-12-19 16:01 |
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cel…
|
English | 79.0 KB | ||
| 2024-12-19 16:01 |
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cel…
|
English | 36.2 KB | ||
| 2024-12-09 17:01 |
Pluri Shortlisted for CDMO of the Year Award by
Advanced Therapies Awards 2025
|
English | 91.1 KB | ||
| 2024-12-09 17:01 |
Pluri Shortlisted for CDMO of the Year Award by
Advanced Therapies Awards 2025
|
English | 36.2 KB | ||
| 2024-11-28 00:27 |
Form 8k-The Company received a letter from Nasdaq Stock Market notifying the C…
|
English | 115.5 KB | ||
| 2024-11-28 00:27 |
Form 8k-The Company received a letter from Nasdaq Stock Market notifying the C…
|
English | 36.3 KB | ||
| 2024-11-25 16:40 |
PLURI Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Sy…
|
English | 70.1 KB | ||
| 2024-11-25 16:40 |
PLURI Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Sy…
|
English | 36.2 KB | ||
| 2024-11-13 00:12 |
Form 10Q For the quarterly period ended September 30, 2024
|
English | 1.4 MB | ||
| 2024-11-13 00:12 |
Form 10Q For the quarterly period ended September 30, 2024
|
English | 36.5 KB | ||
| 2024-10-28 14:02 |
Pluri Collaborates with Bar-Ilan University to Advance Cancer
Immunotherapy fo…
|
English | 116.1 KB | ||
| 2024-10-28 14:02 |
Pluri Collaborates with Bar-Ilan University to Advance Cancer
Immunotherapy fo…
|
English | 36.2 KB | ||
| 2024-10-01 17:13 |
Form 8k -notification from NASDAQ on compliance with the equity requirement
|
English | 110.8 KB | ||
| 2024-10-01 17:13 |
Form 8k -notification from NASDAQ on compliance with the equity requirement
|
English | 36.3 KB | ||
| 2024-10-01 01:09 |
FORM 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES-Liat Zalts
|
English | 133.2 KB |
Automate Your Workflow. Get a real-time feed of all Pluri Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pluri Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pluri Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
